PTC Therapeutics, Inc. Operating Lease, Expense
PTC Therapeutics, Inc. (PTCT) reported Operating Lease, Expense of $21.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-19
- PTC Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $5.40M, a 0.00% change year-over-year.
- PTC Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $5.50M, a 6.78% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, expense for the quarter ending 2025-06-30 was $5.20M, a 23.53% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, expense for the quarter ending 2025-03-31 was $5.00M, a 27.54% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, expense for fiscal 2025 was $21.10M, a 15.26% decline from fiscal 2024.
- PTC Therapeutics, Inc. operating lease, expense for fiscal 2024 was $24.90M, a 14.14% decline from fiscal 2023.
- PTC Therapeutics, Inc. operating lease, expense for fiscal 2023 was $29.00M, a 15.08% increase from fiscal 2022.
- PTC Therapeutics, Inc. operating lease, expense for fiscal 2022 was $25.20M, a 17.76% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.90M derived: sum of 2 quarters · filed 2026-02-19 | $16.10M derived: sum of 3 quarters · filed 2026-02-19 | $21.10M 10-K · filed 2026-02-19 |
| 2025-09-30 | $5.50M 10-Q · filed 2025-11-04 | $10.70M derived: sum of 2 quarters · filed 2025-11-04 | $15.70M 10-Q · filed 2025-11-04 | $21.10M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-06-30 | $5.20M 10-Q · filed 2025-08-07 | $10.30M 10-Q · filed 2025-08-07 | $15.60M derived: sum of 3 quarters · filed 2026-02-19 | $21.50M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-03-31 | $5.00M 10-Q · filed 2025-05-06 | $10.40M derived: sum of 2 quarters · filed 2026-02-19 | $16.30M derived: sum of 3 quarters · filed 2026-02-19 | $23.10M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $11.30M derived: sum of 2 quarters · filed 2026-02-19 | $18.10M derived: sum of 3 quarters · filed 2026-02-19 | $24.90M 10-K · filed 2026-02-19 |
| 2024-09-30 | $5.90M 10-Q · filed 2025-11-04 | $12.70M derived: sum of 2 quarters · filed 2025-11-04 | $19.50M 10-Q · filed 2025-11-04 | $27.10M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $6.80M 10-Q · filed 2025-08-07 | $13.60M 10-Q · filed 2025-08-07 | $21.20M derived: sum of 3 quarters · filed 2026-02-19 | $28.30M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $6.90M 10-Q · filed 2025-05-06 | $14.40M derived: sum of 2 quarters · filed 2026-02-19 | $21.50M derived: sum of 3 quarters · filed 2026-02-19 | $28.70M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $14.60M derived: sum of 2 quarters · filed 2026-02-19 | $21.80M derived: sum of 3 quarters · filed 2026-02-19 | $29.00M 10-K · filed 2026-02-19 |
| 2023-09-30 | $7.10M 10-Q · filed 2024-11-07 | $14.30M derived: sum of 2 quarters · filed 2024-11-07 | $21.50M 10-Q · filed 2024-11-07 | $28.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $7.20M 10-Q · filed 2024-08-08 | $14.30M 10-Q · filed 2024-08-08 | $21.50M derived: sum of 3 quarters · filed 2025-02-27 | $28.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $7.10M 10-Q · filed 2024-04-25 | $14.30M derived: sum of 2 quarters · filed 2025-02-27 | $21.10M derived: sum of 3 quarters · filed 2025-02-27 | $27.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.00M derived: sum of 2 quarters · filed 2025-02-27 | $19.90M derived: sum of 3 quarters · filed 2025-02-27 | $25.20M 10-K · filed 2025-02-27 |
| 2022-09-30 | $6.80M 10-Q · filed 2023-10-26 | $12.70M derived: sum of 2 quarters · filed 2023-10-26 | $18.00M 10-Q · filed 2023-10-26 | $23.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $5.90M 10-Q · filed 2023-08-03 | $11.20M 10-Q · filed 2023-08-03 | $16.70M derived: sum of 3 quarters · filed 2024-02-29 | $22.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $5.30M 10-Q · filed 2023-04-27 | $10.80M derived: sum of 2 quarters · filed 2024-02-29 | $16.10M derived: sum of 3 quarters · filed 2024-02-29 | $21.30M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $10.80M derived: sum of 2 quarters · filed 2024-02-29 | $16.00M derived: sum of 3 quarters · filed 2024-02-29 | $21.40M 10-K · filed 2024-02-29 |
| 2021-09-30 | $5.30M 10-Q · filed 2022-10-27 | $10.50M derived: sum of 2 quarters · filed 2022-10-27 | $15.90M 10-Q · filed 2022-10-27 | $21.00M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $5.20M 10-Q · filed 2022-08-04 | $10.60M 10-Q · filed 2022-08-04 | $15.70M derived: sum of 3 quarters · filed 2023-02-21 | $20.90M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $5.40M 10-Q · filed 2022-05-03 | $10.50M derived: sum of 2 quarters · filed 2023-02-21 | $15.70M derived: sum of 3 quarters · filed 2023-02-21 | $18.30M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $10.30M derived: sum of 2 quarters · filed 2023-02-21 | $12.90M derived: sum of 3 quarters · filed 2023-02-21 | $15.30M 10-K · filed 2023-02-21 |
| 2020-09-30 | $5.20M 10-Q · filed 2021-10-28 | $7.80M derived: sum of 2 quarters · filed 2021-10-28 | $10.20M 10-Q · filed 2021-10-28 | $12.40M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $2.60M 10-Q · filed 2021-07-29 | $5.00M 10-Q · filed 2021-07-29 | $7.20M derived: sum of 3 quarters · filed 2022-02-22 | $8.90M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $2.40M 10-Q · filed 2021-05-04 | $4.60M derived: sum of 2 quarters · filed 2022-02-22 | $6.30M derived: sum of 3 quarters · filed 2022-02-22 | $7.40M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $3.90M derived: sum of 2 quarters · filed 2022-02-22 | $5.00M derived: sum of 3 quarters · filed 2022-02-22 | $6.00M 10-K · filed 2022-02-22 |
| 2019-09-30 | $1.70M 10-Q · filed 2020-10-29 | $2.80M derived: sum of 2 quarters · filed 2020-10-29 | $3.80M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $1.10M 10-Q · filed 2020-08-05 | $2.10M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $1.00M 10-Q · filed 2020-04-30 | |||
| 2018-12-31 | $2.70M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $2.20M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $2.20M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |